Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yan Tu

Showing results (281-290 of 321) with videos related to

Pageof 33
Sort By:
Lung Cancer (Amsterdam, Netherlands)|October 30, 2020
Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective studyJiang-Tao Cheng, Yi-Hui Yao, Yu-Er Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2025
Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung CancerJia-Tao Zhang, Si-Yang Liu, Xuan Gao, et al.
JTO Clinical and Research Reports|January 6, 2025
Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for <i>EGFR</i>-Mutated NSCLC After Complete ResectionSong Dong, Bingfa Yan, Si-Yang Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 23, 2017
Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade ImmunotherapySi-Pei Wu, Ri-Qiang Liao, Hai-Yan Tu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 2, 2018
EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor OsimertinibQi Zhang, Xu-Chao Zhang, Jin-Ji Yang, et al.
Cell Reports|May 7, 2025
T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activityYuanbin Cui, Tingjie Yuan, Ying Wang, et al.
Oncotarget|August 18, 2016
Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterationsNa-Na Lou, Xu-Chao Zhang, Hua-Jun Chen, et al.
Cell Reports|July 12, 2023
T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activityYuanbin Cui, Tingjie Yuan, Ying Wang, et al.
Thoracic Cancer|July 7, 2018
Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancerJin Kang, Hua-Jun Chen, Xu-Chao Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|December 15, 2020
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)Shun Lu, Jie Wang, Ying Cheng, et al.
Pageof 33

Showing results (281-290 of 321) with videos related to

Sort By:
Pageof 33
Lung Cancer (Amsterdam, Netherlands)|October 30, 2020
Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective studyJiang-Tao Cheng, Yi-Hui Yao, Yu-Er Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2025
Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung CancerJia-Tao Zhang, Si-Yang Liu, Xuan Gao, et al.
JTO Clinical and Research Reports|January 6, 2025
Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for <i>EGFR</i>-Mutated NSCLC After Complete ResectionSong Dong, Bingfa Yan, Si-Yang Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 23, 2017
Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade ImmunotherapySi-Pei Wu, Ri-Qiang Liao, Hai-Yan Tu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 2, 2018
EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor OsimertinibQi Zhang, Xu-Chao Zhang, Jin-Ji Yang, et al.
Cell Reports|May 7, 2025
T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activityYuanbin Cui, Tingjie Yuan, Ying Wang, et al.
Oncotarget|August 18, 2016
Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterationsNa-Na Lou, Xu-Chao Zhang, Hua-Jun Chen, et al.
Cell Reports|July 12, 2023
T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activityYuanbin Cui, Tingjie Yuan, Ying Wang, et al.
Thoracic Cancer|July 7, 2018
Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancerJin Kang, Hua-Jun Chen, Xu-Chao Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|December 15, 2020
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)Shun Lu, Jie Wang, Ying Cheng, et al.
Pageof 33